Arbutus Biopharma Corp

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases, specifically the treatment of chronic hepatitis B (cHBV). The company's business model revolves around the development of proprietary therapeutic candidates and the protection and monetization of its intellectual property, particularly its patented lipid nanoparticle (LNP) technology. Revenue is generated primarily through collaboration agreements, license agreements, and royalty entitlements from the use of its licensed technologies. The company has incurred operating losses in nearly every year since its inception, with an accumulated net deficit of approximately $1.4 billion ¹ as of December 31, 2025, and has not yet generated product revenues.

The company's core business model involves developing and advancing product candidates through clinical trials, with a long-term goal of achieving a functional cure for cHBV. This includes a mix of internal development and strategic partnerships. Revenue streams are primarily non-recurring upfront payments, milestone payments, and royalties from licensing its LNP technology, as well as potential future product sales if its candidates achieve regulatory approval. Primary customer segments, if products are commercialized, would be patients with cHBV infection and healthcare providers.

The company's product pipeline includes two main candidates for cHBV: imdusiran (AB-729) and AB-101. Imdusiran is a proprietary, GalNAc-conjugated, subcutaneously-delivered RNAi therapeutic designed to suppress all HBV antigens, including HBsAg, HBV DNA, and HBV RNA. Over 200 patients ² with cHBV infection have been dosed with imdusiran in Phase 1 and Phase 2a clinical trials, showing meaningful reductions in viral markers and leading to functional cure in some patients, with benefits observed across all evaluated HBV genotypes (A to E). A total of 10 patients ³ have achieved functional cure during Phase 2a clinical trials and long-term follow-up. AB-101 is a proprietary oral PD-L1 inhibitor aimed at activating patients' HBV-specific immune response. It is currently in a Phase 1a/1b clinical trial (AB-101-001) evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects and cHBV patients. Data from Parts 1 and 2 in healthy subjects and Part 3 in cHBV patients showed AB-101 was generally well-tolerated with evidence of high receptor occupancy, with maximal PD-L1 receptor occupancy between 68-100% ⁴ at the 30mg daily dose.

For the fiscal year ended December 31, 2025, the company reported total revenue of $14.083 million ⁵, an increase from $6.171 million ⁶ in 2024. This was primarily driven by an increase of $9.1 million ⁷ in revenue recognized from the Qilu license agreement due to the conclusion of the strategic partnership in June 2025, and $0.5 million ⁸ from a contractual milestone related to Alnylam's use of LNP technology. Operating expenses decreased to $52.243 million ⁹ in 2025 from $82.490 million ¹⁰ in 2024. The net loss attributable to common shares for 2025 was $33.501 million ¹¹, or a loss of $0.17 ¹² per basic and diluted common share, compared to a net loss of $69.920 million ¹³, or a loss of $0.38 ¹⁴ per basic and diluted common share, in 2024. Cash and cash equivalents were $18.008 million ¹⁵ as of December 31, 2025, with investments in marketable securities of $73.463 million ¹⁶, totaling $91.471 million ¹⁷ in cash, cash equivalents, and marketable securities. The company had no outstanding debt as of December 31, 2025.

Year-over-year, total revenue increased by $7.9 million ¹⁸ in 2025 compared to 2024. Revenue from collaborations and licenses increased from $3.919 million ¹⁹ in 2024 to $12.601 million ²⁰ in 2025, largely due to the Qilu agreement. Non-cash royalty revenue decreased from $2.252 million ²¹ in 2024 to $1.482 million ²² in 2025. Research and development expenses decreased by $28.8 million ²³ in 2025 to $25.241 million ²⁴ from $54.037 million ²⁵ in 2024. General and administrative expenses decreased by $6.2 million ²⁶ to $15.893 million ²⁷ in 2025 from $22.108 million ²⁸ in 2024. The change in fair value of contingent consideration resulted in a decrease of $1.830 million ²⁹ in 2025, compared to an increase of $2.625 million ³⁰ in 2024. Restructuring costs increased to $12.939 million ³¹ in 2025 from $3.720 million ³² in 2024. Interest income decreased by $2.5 million ³³ in 2025 to $4.068 million ³⁴ from $6.585 million ³⁵ in 2024.

Significant operational developments during 2025 included streamlining the organization to focus on imdusiran and AB-101, ceasing all discovery efforts, halting preparations for a potential IM-PROVE III clinical trial, and reducing the workforce by an additional 57% ³⁶ in the first quarter of 2025, following a 40% ³⁷ reduction in 2024. The company also exited its corporate headquarters in Warminster, Pennsylvania, and discontinued in-house scientific research, incurring one-time restructuring charges of $12.9 million ³⁸. In June 2025, a new Scientific Advisory Board (SAB) was launched to advise on the strategic evaluation of the cHBV pipeline. In August 2025, Dr. Roger Sawhney was appointed to the Board of Directors. In June 2025, the strategic partnership with Qilu Pharmaceutical Co., Ltd. was mutually concluded, and the company now holds global rights for imdusiran. In December 2025, the company recognized revenue of $0.5 million ³⁹ from a contractual milestone related to Alnylam's use of its LNP technology in an additional product candidate to treat hepatocellular carcinoma (HCC).

The company expects to maintain its reduced net cash burn in 2026 due to organizational changes implemented in 2024 and 2025 and ongoing cost management efforts. Substantial additional funds will be required in the future to continue the active development of its pipeline products and technologies.

The company's primary growth areas are focused on maximizing opportunities for its cHBV development programs, specifically imdusiran and AB-101, and through its exclusive license with Genevant, its in-house developed LNP technology. The strategy for cHBV is to develop a functional cure for patients with imdusiran as a potential cornerstone in combination therapy, aiming to suppress HBV DNA replication, HBV RNA transcription, and HBsAg and other viral protein expression, while boosting HBV-specific immune response. The company is also evaluating imdusiran's potential to suppress HBV DNA replication and HBV RNA and HBsAg expression without immunotherapeutics and is refining potential Phase 2b clinical trial designs for imdusiran.

Operationally, the company has undertaken significant restructuring actions to reduce its cost base. In 2024, the company streamlined its organization by ceasing all discovery efforts, halting preparations for a potential IM-PROVE III clinical trial, and reducing its workforce by 40% ⁴⁰. In the first quarter of 2025, the Board further reduced the workforce by an additional 57% ⁴¹, decided to exit its corporate headquarters in Warminster, Pennsylvania, and discontinued in-house scientific research. These actions resulted in one-time restructuring charges of $12.9 million ⁴² in 2025. The company expects these organizational changes and ongoing cost management efforts to significantly reduce its net cash burn in 2025 compared to 2024 and to maintain this reduced burn in 2026.

Planned capital allocation includes funding for prosecuting and enforcing patent claims and other intellectual property rights, including the ongoing patent infringement matter against Pfizer/BioNTech, the Moderna §1498 Appeal (if filed by Moderna), and the lawsuit against the United States. The company is currently evaluating a return of capital to its shareholders in the third quarter of calendar year 2026 ⁴³, following the receipt of its portion of the Noncontingent Settlement Payment from Moderna. Funding needs will also depend on revenues from legacy collaborative partnerships and licensing agreements, including potential royalty payments from Alnylam's ONPATTRO, and milestone and royalty payments from ongoing collaborative partnerships.

The company explicitly flagged several structural headwinds and execution risks. The possibility and timing of any possible reversion of the ONPATTRO royalty entitlement from OMERS is affected by factors such as Alnylam's ability to effectively market and sell ONPATTRO, the amount and timing of sales, regulatory approvals, pricing, insurance coverage, reimbursement, and competition, including from Alnylam's next-generation RNAi product AMVUTTRA, which has cannibalized ONPATTRO sales. If ONPATTRO sales continue to decline, the royalty entitlement may never revert to the company. The company also faces risks associated with the Contingent Settlement Payment under the Moderna Settlement Agreement, as it is payable in full only upon an Arbutus/Genevant §1498 Victory, and there is no assurance of timely receipt or even receipt at all. Furthermore, under certain circumstances, the company and Genevant may be required to return any Contingent Settlement Payment received, plus interest, if an Arbutus/Genevant §1498 Victory is subsequently overturned.

The company faces substantial risks, including those related to ongoing patent infringement lawsuits against Pfizer/BioNTech and the United States, which require significant resource expenditure with uncertain outcomes. The Moderna Settlement Agreement includes a contingent lump sum payment of up to an aggregate $1.3 billion ⁴⁴ to the company and Genevant, which is subject to a favorable ruling in a limited appeal related to 28 U.S.C. §1498, and there is no assurance of timely receipt or that the full amount will be received, with a risk of repayment if the ruling is overturned. The company is in early stages of development, with no product revenues to date, and has incurred an accumulated net deficit of approximately $1.4 billion ⁴⁵ as of December 31, 2025. Substantial additional capital will be required to fund operations, and if not available, development and commercialization programs may be delayed, limited, or eliminated. Clinical trials for product candidates are expensive, time-consuming, and uncertain, with preclinical and interim data not necessarily predictive of later success. The clinical hold on the AB-101 IND application by the FDA may take considerable time and expense to resolve, with no assurance of removal. Even if approved, products remain subject to ongoing regulatory requirements and significant competition from well-capitalized biotechnology and pharmaceutical companies, which could render products obsolete. Product liability lawsuits pose a risk, with current insurance coverage limited to $10 million ⁴⁶ per occurrence and $10 million ⁴⁷ in aggregate. Coverage and adequate reimbursement for product candidates are uncertain, potentially hindering profitable sales. The company is subject to complex and evolving U.S. and Canadian healthcare laws and regulations, including anti-kickback, false claims, and privacy laws, with potential for criminal sanctions, civil penalties, and reputational harm for non-compliance. Failure to comply with governmental pricing programs like Medicaid Drug Rebate Program, 340B program, and Medicare Part B and D could result in penalties and reduced revenues. The Inflation Reduction Act of 2022 and the "One Big Beautiful Bill Act" of 2025 introduce further cost containment measures and drug price negotiation programs that could negatively impact future revenues. The company's reliance on third parties for clinical trials and manufacturing exposes it to risks of delays, quality issues, and higher costs. Intellectual property rights are subject to challenges, as evidenced by the invalidation of a patent in the LNP portfolio and the revocation of the '254 Patent by the EPO in January 2026. Cybersecurity threats are increasing in sophistication, and despite robust programs, system failures or breaches could lead to financial, legal, business, or reputational harm.

Management's message to shareholders emphasizes a focused strategy on maximizing opportunities for its cHBV development programs, imdusiran and AB-101, and leveraging its LNP delivery technology through its exclusive license with Genevant. The company has undertaken significant restructuring, including ceasing all discovery efforts, halting preparations for a potential IM-PROVE III clinical trial, and reducing its workforce by 40% ⁴⁸ in 2024 and an additional 57% ⁴⁹ in the first quarter of 2025, to streamline operations and focus on clinical development. Management expects these changes and ongoing cost management efforts to significantly reduce its net cash burn in 2025 compared to 2024 and to maintain this reduced burn in 2026. A key forward-looking statement is the expectation of receiving an aggregate $950.0 million ⁵⁰ noncontingent lump sum payment from Moderna on or before July 8, 2026 ⁵¹, with an additional contingent payment of up to an aggregate $1.3 billion ⁵² upon a favorable ruling in the Moderna §1498 Appeal. The company is currently evaluating a return of capital to shareholders in the third quarter of calendar year 2026 ⁵³, following the receipt of its portion of the Noncontingent Settlement Payment. Strategic priorities include advancing the clinical development of imdusiran and AB-101, protecting and defending its intellectual property, and evaluating a return of capital to shareholders.